

**Fw: FOR INFORMATION – Study eligible for NIHR CRN support IRAS ID [290474]  
CPMS ID [50728]**

Roffe, Christine (RJE) UHNM &lt;Christine.Roffe@uhnm.nhs.uk&gt;

Wed 13/10/2021 22:31

To: Lesia Kurlak (staff) &lt;mgzlok@exmail.nottingham.ac.uk&gt;; Cameron Skinner &lt;mszcjs1@exmail.nottingham.ac.uk&gt;; Olivia Matthews &lt;mszogn@exmail.nottingham.ac.uk&gt;

 1 attachments (144 KB)

Working Together Effectively to Deliver your Study .pdf;

We now have portfolio approval. More info to come soon.

With best wishes

*Christine*

C. Roffe MD FRCP FESO  
Professor of Stroke Medicine, Keele University  
Stoke-on-Trent ST4 7QB  
T: 01782 671655  
<http://www.stroke-in-stoke.info/>

---

**From:** thomas.hustler@nhr.ac.uk <thomas.hustler@nhr.ac.uk> on behalf of Portfolio Applications Team <portfolio.applications@nhr.ac.uk>

**Sent:** 13 October 2021 15:23

**To:** Roffe, Christine (RJE) UHNM

**Cc:** sponsor; Support Study East Midlands; Roz Sorrie-Rae

**Subject:** FOR INFORMATION – Study eligible for NIHR CRN support IRAS ID [290474] CPMS ID [50728]

This message was received from **outside** of UHNM. **STOP**. Were you expecting this email? Does it look genuine? **THINK**. Before you **CLICK** on links or **OPEN** any attachments

Dear Christine,

**RE: IRAS [290474] - [Metoclopramide for Avoiding Pneumonia after Stroke (MAPS-2) Trial]**

I am pleased to inform you that your study has been deemed eligible for NIHR Clinical Research Network support. Further information about CRN support can be found on our [website](#).

**Local Clinical Research Networks (LCRN)**

The 15 LCRNs cover the length and breadth of England and are available to coordinate and support the delivery of research across the NHS in England.

Your Lead LCRN is East Midlands. The LCRN is copied into this email and will be in touch to discuss the support available to your study. In the meantime, further information about your

local network, including contact details should you have any questions, can be found on our [website](#).

The Lead LCRN may be able to help you with communications and engagement around your study - please contact the LCRN communications team to find out more.

In May 2019, NIHR published its [policy on the registration and disclosure of clinical trials](#). The policy aims to improve practice in prospective registration and timely disclosure of results in order to ensure full transparency of clinical trials funded by NIHR. This policy applies to all Clinical Trials actively recruiting on or after 20 May 2019 where all of the research costs (as defined by [AcoRD](#)) are funded by the NIHR. It is your responsibility to check whether your study falls within the scope of this policy and if so, to work with your Sponsor organisation and Clinical Trial Unit partners to ensure adherence. The spirit of this policy does apply to all NIHR research and therefore all studies should work towards following the principles within it. The NIHR will undertake an annual audit and publish a report of the level of compliance for all clinical trials in scope.

### Next Steps

A member of the team will be in touch shortly to collect any additional information required for inclusion of your study on the Central Portfolio Management System (CPMS), and then to confirm the NIHR CRN Specialty which your study has been allocated to. This is the Specialty that will be best placed to support the delivery of your study; it may not be representative of the subject area of your research and it can be changed if required.

The LCRN for each participating site is now able to provide support to undertake NHS Support activities for this study as per their local model. These models may vary and therefore agreement with the LCRN for each participating site is required. To note, provision of NHS Support Activities is informed by the attribution of study specific activities as NHS Support Activities. This is agreed once on behalf of the CRN by the Lead LCRN AcoRD Specialist at the Lead LCRN, in line with [AcoRD policy](#).

If your study has not yet received Health Research Authority (HRA) Approval then your application will continue; should you have any questions about HRA Approval, contact the HRA at [hra.approval@nhs.net](mailto:hra.approval@nhs.net).

Kind regards

Tom

### Portfolio Eligibility

**CRN Research Delivery** | CRN National Coordinating Centre (CRNCC) | NIHR Clinical Research Network (CRN)



e. [portfolio.applications@nhr.ac.uk](mailto:portfolio.applications@nhr.ac.uk)

a. 21 Queen Street, Leeds, LS1 2TW

We would really appreciate you taking 5-10 minutes to tell us about your experience of working with us. Providing this feedback will help us to understand how we can improve our service to you. Please click here to complete our survey: <https://leeds.onlinesurveys.ac.uk/tell-us-about-your-experiences-of-working-with-the-clinica-2>

NIHR Signature

Follow us: FB Logo [OfficialNIHR](#) | Twitter logo [@NIHRresearch](#) | LI Logo [NIHR](#) |

Youtube Logo [NIHRtv](#) | URL Logo [nhr.ac.uk](http://nhr.ac.uk)

Confidential information may be contained in this message. If you are not the intended recipient, any reading, printing, storage, disclosure, copying or any other action taken in respect of this e-mail is prohibited and may be unlawful. If you are not the intended recipient,

please notify the sender immediately by using the reply function and then permanently delete what you have received.